Molecular Insight into the Steric Shielding Effect of PEG on the Conjugated Staphylokinase: Biochemical Characterization and Molecular Dynamics Simulation
PEGylation is a successful approach to improve potency of a therapeutic protein. The improved therapeutic potency is mainly due to the steric shielding effect of PEG. However, the underlying mechanism of this effect on the protein is not well understood, especially on the protein interaction with its high molecular weight substrate or receptor. Here, experimental study and molecular dynamics simulation were used to provide molecular insight into the interaction between the PEGylated protein and its receptor. Staphylokinase (Sak), a therapeutic protein for coronary thrombolysis, was used as a model protein. Four PEGylated Saks were prepared by site-specific conjugation of 5 kDa/20 kDa PEG to N-terminus and C-terminus of Sak, respectively. Experimental study suggests that the native conformation of Sak is essentially not altered by PEGylation. In contrast, the bioactivity, the hydrodynamic volume and the molecular symmetric shape of the PEGylated Sak are altered and dependent on the PEG chain length and the PEGylation site. Molecular modeling of the PEGylated Saks suggests that the PEG chain remains highly flexible and can form a distinctive hydrated layer, thereby resulting in the steric shielding effect of PEG. Docking analyses indicate that the binding affinity of Sak to its receptor is dependent on the PEG chain length and the PEGylation site. Computational simulation results explain experimental data well. Our present study clarifies molecular details of PEG chain on protein surface and may be essential to the rational design, fabrication and clinical application of PEGylated proteins.
Milla P, Dosio F, Cattel L (2012) PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery. Curr Drug Metab 13: 105–119.
[3]
Greenwald RB, Choe YH, McGuire J, Conover CD (2003) Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 55: 217–250.
[4]
Fishburn CS (2008) The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci 97: 4167–4183.
[5]
Zheng JC, Lei N, He QC, Hu W, Jin JG, et al. (2012) PEGylation is effective in reducing immunogenicity, immunotoxicity, and hepatotoxicity of alpha-momorcharin in vivo. Immunopharmacol Immunotoxicol 34: 866–873.
[6]
Wattendorf U, Merkle HP (2008) PEGylation as a tool for the biomedical engineering of surface modified microparticles. J Pharm Sci 97: 4655–4669.
[7]
Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, et al. (2000) Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 97: 8548–8553.
[8]
Cazalis CS, Haller CA, Sease-Cargo L, Chaikof EL (2004) C-terminal site-specific PEGylation of a truncated thrombomodulin mutant with retention of full bioactivity. Bioconjug Chem 15: 1005–1009.
[9]
Dellacherie E, Leonard M (1991) Improvement of oxygen-carrying properties of human hemoglobin by chemical modification with a benzene hexacarboxylate-monosubstituted polyoxyethylene. J Protein Chem 10: 61–67.
[10]
Knusli C, Delgado C, Malik F, Domine M, Tejedor MC, et al. (1992) Polyethylene-glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity. Br J Haematol 82: 654–663.
[11]
Chiu K, Agoubi LL, Lee I, Limpar MT, Lowe JW, et al. (2010) Effects of polymer molecular weight on the size, activity, and stability of PEG-functionalized trypsin. Biomacromolecules 11: 3688–3692.
[12]
Tian P, Andricioaei I (2006) Size, motion, and function of the SecY translocon revealed by molecular dynamics simulations with virtual probes. Biophys J 90: 2718–2730.
[13]
Lee HJ, Srinivasan D, Coomber D, Lane DP, Verma CS (2007) Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: A computational study. Cell Cycle 6: 2604–2611.
[14]
Manjula BN, Tsai S, Upadhya R, Perumalsamy K, Smith PK, et al. (2003) Site-specific PEGylation of hemoglobin at cys-93(beta): Correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain. Bioconjug Chem 14: 464–472.
[15]
Yang C, Lu DN, Liu Z (2011) How PEGylation enhances the stability and potency of insulin: A molecular dynamics simulation. Biochemistry 50: 2585–2593.
[16]
Collen D, Schlott B, Engelborghs Y, Vanhoef B, Hartmann M, et al. (1993) On the mechanism of the activation of human plasminogen by recombinant staphylokinase. J Chem Biol 268: 8284–8289.
[17]
Okada K, Ueshima S, Tanaka M, Fukao H, Matsuo O (2000) Analysis of plasminogen activation by the plasmin-staphylokinase complex in plasma of alpha(2)-antiplasmin-deficient mice. Blood Coagul Fibrinolysis 11: 645–655.
[18]
Liu RY, Li DX, Wang J, Qiu R, Lin QX, et al. (2012) Preparation, characterization and in vitro bioactivity of N-terminally PEGylated staphylokinase dimers. Process Biochem 47: 41–46.
[19]
Ohlenschlager O, Ramachandran R, Guhrs KH, Schlott B, Brown LR (1998) Nuclear magnetic resonance solution structure of the plasminogen-activator protein staphylokinase. Biochemistry 37: 10635–10642.
[20]
Mark Thompson (2004) ArgusLab 4.0.1. Planaria Software LLC. Available: http://www.arguslab.com/arguslab.com/Arg？usLab.html. Accessed 2012 Feb 16.
[21]
Van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, et al. (2005) GROMACS: Fast, flexible, and free. J Comput Chem 26: 1701–1718.
[22]
Oostenbrink C, Villa A, Mark AE, van Gunsteren WF (2004) A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6. J Comput Chem 25: 1656–1676.
Winger M, de Vries AH, van Gunsteren WF (2009) Force-field dependence of the conformational properties of α,ω-dimethoxypolyethylene glycol. Molecular Physics 107: 1313–1321.
[25]
Humphrey W, Dalke A, Schulten K (1996) VMD: Visual molecular dynamics. J Mol Graph 14: 33–38.
[26]
Peisach E, Wang JY, de los Santos T, Reich E, Ringe D (1999) Crystal structure of the proenzyme domain of plasminogen. Biochemistry 38: 11180–11188.
[27]
Ritchie DW (2003) Evaluation of protein docking predictions using Hex 3.1 in CAPRI Rounds 1-2. Proteins 52: 98–106.
[28]
Parry MAA, Fernandez-Catalan C, Bergner A, Huber R, Hopfner KP, et al. (1998) The ternary microplasmin-staphylokinase-microplasmin complex is a proteinase-cofactor-substrate complex in action. Nat Struct Biol 5: 917–923.
[29]
Dhalluin C, Ross A, Leuthold LA, Foser S, Gsell B, et al. (2005) Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha(2a) and its individual positional isomers. Bioconjug Chem 16: 504–517.
[30]
Lebowitz J, Lewis MS, Schuck P (2002) Modern analytical ultracentrifugation in protein science: A tutorial review. Protein Sci 11: 2067–2079.
[31]
Jespers L, Vanwetswinkel S, Lijnen HR, Van Herzeele N, Van Hoef B, et al. (1999) Structural and functional basis of plasminogen activation by staphylokinase. Thromb Haemost 81: 479–485.
[32]
Hu T, Li D, Wang J, Wang Q, Liang Y, et al. (2012) Propylbenzmethylation at Val-1(α) markedly increases the tetramer stability of the PEGylated hemoglobin: a comparison with propylation at Val-1(α). Biochim Biophys Acta 1820: 2044–2051.
[33]
Wang J, Hu T, Liu Y, Zhang G, Ma G, et al. (2011) Kinetic and stoichiometric analysis of the modification process for N-terminal PEGylation of staphylokinase. Anal Biochem 412: 114–116.
